Prospective study of repeated biopsy feasibility and acquired resistance at disease progression in patients with advanced EGFR mutant lung cancer treated with erlotinib in a phase 2 trial
Mené sur 60 patients atteints d'un cancer du poumon non à petites cellules de stade IV avec mutations du gène EGFR et traités par erlotinib (âge médian : 62,5 ans), cet essai de phase II évalue la possibilité de réaliser plusieurs biopsies lors de la progression de la maladie pour identifier les mécanismes de résistance au traitement et adapter la stratégie thérapeutique
Tumor genotyping is standard-of-care for patients with advanced non–small-cell lung cancer (NSCLC),1 but treatment decisions for patients with progressive disease increasingly depend on identifying the specific mechanism of acquired resistance.2,3 To our knowledge, a comprehensive assessment of consent to undergo a repeated biopsy and logistical outcomes in patients receiving targeted therapy has not been prospectively evaluated in a single study; thus we performed a phase 2 prospective analysis of repeated biopsy in patients with advanced, tyrosine kinase inhibitor (TKI)-naïve, EGFR-mutant NSCLC treated with erlotinib until progression.
JAMA Oncology , résumé, 2015